Psychedelic drugs come with stigma but multiple researchers have made important discoveries on their efficacy in treating multiple disorders. MDMA improved PTSD for 86% of drug trial participants, with 71% entering remission. Paired with talk therapy, single doses of psilocybin and ketamine rapidly improved treatment-resistant depression. A dose of LSD led to a 48% remission rate in generalized anxiety sufferers, earning FDA breakthrough status. Healing the brain via “neural plasticity,” the drugs are being tested to treat dementia, alcohol use disorder, OCD, TBIs and more. Currently, only ketamine is clinically approved, while the others remain limited to lab settings.